593 related articles for article (PubMed ID: 32973814)
1. Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury.
Chen X; Guo H; Qiu L; Zhang C; Deng Q; Leng Q
Front Immunol; 2020; 11():2056. PubMed ID: 32973814
[TBL] [Abstract][Full Text] [Related]
2. Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines.
Vitte J; Michel M; Mezouar S; Diallo AB; Boumaza A; Mege JL; Desnues B
Front Immunol; 2020; 11():2159. PubMed ID: 32983179
[TBL] [Abstract][Full Text] [Related]
3. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
[TBL] [Abstract][Full Text] [Related]
4. Drug repurposing and cytokine management in response to COVID-19: A review.
Heimfarth L; Serafini MR; Martins-Filho PR; Quintans JSS; Quintans-Júnior LJ
Int Immunopharmacol; 2020 Nov; 88():106947. PubMed ID: 32919216
[TBL] [Abstract][Full Text] [Related]
5. Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.
Menendez JA
Aging (Albany NY); 2020 May; 12(10):8760-8765. PubMed ID: 32463794
[TBL] [Abstract][Full Text] [Related]
6. Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19.
Schumann S; Kaiser A; Nicoletti F; Mangano K; Fagone P; van Wijk E; Yan Y; Schulz P; Ludescher B; Niedermaier M; von Wegerer J; Rauch P; Setz C; Schubert U; Brysch W
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233817
[TBL] [Abstract][Full Text] [Related]
7. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
Yaqinuddin A; Kashir J
Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
[TBL] [Abstract][Full Text] [Related]
8. Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?
Severa M; Farina C; Salvetti M; Coccia EM
Front Immunol; 2020; 11():1459. PubMed ID: 32655578
[No Abstract] [Full Text] [Related]
9. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
[TBL] [Abstract][Full Text] [Related]
10. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
Almerie MQ; Kerrigan DD
Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
[TBL] [Abstract][Full Text] [Related]
11. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.
Saini KS; Lanza C; Romano M; de Azambuja E; Cortes J; de Las Heras B; de Castro J; Lamba Saini M; Loibl S; Curigliano G; Twelves C; Leone M; Patnaik MM
Br J Cancer; 2020 Sep; 123(5):694-697. PubMed ID: 32572174
[TBL] [Abstract][Full Text] [Related]
12. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
Nisole S; Saulnier A; Gatignol A
Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
[No Abstract] [Full Text] [Related]
13. Current Perspective of Antiviral Strategies against COVID-19.
Ahidjo BA; Loe MWC; Ng YL; Mok CK; Chu JJH
ACS Infect Dis; 2020 Jul; 6(7):1624-1634. PubMed ID: 32485102
[TBL] [Abstract][Full Text] [Related]
14. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
15. Targeting inflammation and cytokine storm in COVID-19.
Huang Q; Wu X; Zheng X; Luo S; Xu S; Weng J
Pharmacol Res; 2020 Sep; 159():105051. PubMed ID: 32603772
[No Abstract] [Full Text] [Related]
16. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.
Lisi L; Lacal PM; Barbaccia ML; Graziani G
Biochem Pharmacol; 2020 Oct; 180():114169. PubMed ID: 32710969
[TBL] [Abstract][Full Text] [Related]
17. Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19.
El-Missiry MA; El-Missiry ZMA; Othman AI
Eur J Pharmacol; 2020 Sep; 882():173329. PubMed ID: 32615182
[TBL] [Abstract][Full Text] [Related]
18. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
[TBL] [Abstract][Full Text] [Related]
19. Repurposing Existing Drugs for the Treatment of COVID-19.
Farne H; Kumar K; Ritchie AI; Finney LJ; Johnston SL; Singanayagam A
Ann Am Thorac Soc; 2020 Oct; 17(10):1186-1194. PubMed ID: 32692580
[TBL] [Abstract][Full Text] [Related]
20. Old and re-purposed drugs for the treatment of COVID-19.
Jean SS; Hsueh PR
Expert Rev Anti Infect Ther; 2020 Sep; 18(9):843-847. PubMed ID: 32419524
[No Abstract] [Full Text] [Related]
[Next] [New Search]
